{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-085061","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2026-07-20T20:06:12+00:00","discovered_at":"2026-07-20T20:07:02.458169+00:00","generated_at":"2026-07-20T20:07:06.163435+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elutia signs agreement to sell SimpliDerm business for up to $11M, focuses on NXT-41x launch","bullets":["Total consideration up to $11M: $8M cash at closing plus up to $3M in technology transfer and commercial milestone payments over 18 months.","Closing expected in H2 2026, subject to customary conditions; buyer is Cellution Biologics Inc.","Proceeds provide non-dilutive capital to advance NXT-41x toward clearance and commercial launch in 2027.","Divestiture sharpens Elutia's focus on the $1.5B plastic and reconstructive surgery market with NXT-41x.","SimpliDerm is a human acellular dermis product for breast reconstruction; sale completes strategic review."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-085061","json":"https://secwatch.observer/filing/0001104659-26-085061.json","markdown":"https://secwatch.observer/filing/0001104659-26-085061.md","text":"https://secwatch.observer/filing/0001104659-26-085061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926085061/0001104659-26-085061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465926085061/tm2620864d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-20T20:07:06.163435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}